2020
DOI: 10.1186/s41927-020-00150-7
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background Blood accessible biomarkers to assess disease activity and their response to therapies in Juvenile Dermatomyositis (JDM) are urgently needed. This pilot study aims to identify serum protein biomarkers associated with clinical disease activity in untreated JDM and their response to medical therapy. Methods SomaScan® technology screened JDM patients for 1305 proteins at three points: 1) before start of treatment, 2) while on… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
13
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
2
1

Relationship

4
4

Authors

Journals

citations
Cited by 22 publications
(13 citation statements)
references
References 42 publications
0
13
0
Order By: Relevance
“…We had previously used the SOMA protein array technology to test for differences in plasma protein levels of untreated JDM versus controls and whether the protein levels change in response to treatment 29 . We wanted to compare the SOMA plasma results to the PBMC RNA results of this study.…”
Section: Resultsmentioning
confidence: 99%
“…We had previously used the SOMA protein array technology to test for differences in plasma protein levels of untreated JDM versus controls and whether the protein levels change in response to treatment 29 . We wanted to compare the SOMA plasma results to the PBMC RNA results of this study.…”
Section: Resultsmentioning
confidence: 99%
“…Elevated levels of galectin 9, galectin 1, TNFR-2, and CXCL-10 indicted the need for intensification of treatment within the first 3 months, while high CXCL-10 at diagnosis also appeared to be predictive of a longer time to drug-free remission [85]. A recent study, using the Soma ™ Scan technology, identified serum proteins in JDM at various stages of therapy (untreated, on maximal therapy, and when being tapered) which are as follows: (a) responded to therapy, (b) rebounded when therapy was decreased, or (c) never responded to therapy at all-opening up new areas of investigation [86].…”
Section: Accessible Serum Biomarkersmentioning
confidence: 99%
“…We had previously used the SOMA protein array technology to test for differences in plasma protein levels of untreated JDM versus controls and whether the protein levels change in response to treatment (32). We wanted to compare the SOMA plasma results to the PBMC RNA results of this study.…”
Section: Resultsmentioning
confidence: 99%
“…We compared the transcriptional results from untreated JDM PBMCs to the data we published from a previous paper examining sera proteins in untreated JDM as well (32). Overall only 12 protein targets were altered in untreated sera and also differentially expressed in untreated PBMCs.…”
Section: Discussionmentioning
confidence: 99%